Gregory E. Spurlock
Known title: DirectorCIK: 0001578507
Associated companies
Transaction History
| RDNT | ▲ Buy | Grant | 2,946 | $0 | 6/2/2026 | View on chart |
| RDNT | ▲ Buy | Grant | 2,699 | $0 | 6/10/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 7,167 | $428K | 6/18/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 7,167 | $428K | 6/17/2024 | View on chart |
| RDNT | ▲ Buy | Grant | 2,591 | $0 | 6/13/2024 | View on chart |
| RDNT | ▲ Buy | Grant | 4,066 | $0 | 6/7/2023 | View on chart |
| RDNT | ▲ Buy | Grant | 6,269 | $0 | 6/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RadNet Q2 Earnings and AI Study News
RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.
RadNet Q2 Earnings and AI Study News. RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.